Ovid Therapeutics (OVID)
NASDAQ:OVID
Want to see OVID full AI Analyst Report?
Top Page
Ovid Therapeutics
(NASDAQ:OVID)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.50
▼(-14.09% Downside)
Action:Reiterated
Date:06/03/26
The score is held back primarily by weak financial performance (ongoing losses and negative free cash flow) and cautious near-term technicals (below key short-term averages with negative MACD). Offsetting this, recent corporate events improved funding and runway, while valuation metrics are not supportive due to a negative P/E and no dividend yield provided.
Positive Factors
Low leverage / strong balance sheet
Very low debt-to-equity (~0.01 TTM) materially reduces financial risk and preserves strategic optionality. Over the next 2–6 months this lowers bankruptcy risk, improves negotiating leverage with partners, and allows the company to allocate capital to clinical programs without large interest burdens.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow indicate ongoing cash burn that must be covered by financings or partnerships. Over months this constrains R&D pacing, forces dilutive raises or licensing deals, and reduces flexibility to absorb clinical setbacks without new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt-to-equity (~0.01 TTM) materially reduces financial risk and preserves strategic optionality. Over the next 2–6 months this lowers bankruptcy risk, improves negotiating leverage with partners, and allows the company to allocate capital to clinical programs without large interest burdens.
Read all positive factors
Ovid Therapeutics (OVID) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$446.07M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)2.17
Revenue Growth1199.64%
EPS Growth30.81%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding186,640,100
10 Day Avg. Volume1,408,597
30 Day Avg. Volume1,729,792
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.92
Price to Sales (P/S)16.57
P/FCF Ratio-3.14
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue37.55
Enterprise Value/Gross Profit37.74
Enterprise Value/Ebitda-5.62
Forecast
1Y Price Target
$5.33Price Target Upside83.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$221.88K
Ovid Therapeutics Business Overview & Revenue Model
Company Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials f...
How the Company Makes Money
Ovid Therapeutics’ revenue model is typical of a clinical-stage biotechnology company: it may generate income primarily from (a) collaboration and licensing arrangements (such as upfront payments, reimbursement for research and development service...
Ovid Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.12M | 7.25M | 566.00K | 392.00K | 1.50M | 208.38M |
| Gross Profit | 7.09M | 6.95M | 566.00K | 392.00K | 1.50M | 208.38M |
| EBITDA | -47.57M | -42.14M | -57.77M | -57.01M | -54.17M | 124.45M |
| Net Income | -24.17M | -17.41M | -26.43M | -52.34M | -54.17M | 122.83M |
Balance Sheet | ||||||
| Total Assets | 225.63M | 150.93M | 92.17M | 144.03M | 155.27M | 194.54M |
| Cash, Cash Equivalents and Short-Term Investments | 155.52M | 69.64M | 53.08M | 105.83M | 129.00M | 187.80M |
| Total Debt | 1.46M | 13.42M | 14.76M | 16.00M | 16.54M | 0.00 |
| Total Liabilities | 27.36M | 20.27M | 23.94M | 56.23M | 22.99M | 14.80M |
| Stockholders Equity | 198.27M | 130.66M | 68.23M | 87.80M | 132.27M | 179.75M |
Cash Flow | ||||||
| Free Cash Flow | -41.95M | -38.33M | -56.03M | -45.92M | -56.65M | 118.43M |
| Operating Cash Flow | -41.95M | -38.33M | -55.96M | -45.78M | -55.23M | 118.61M |
| Investing Cash Flow | -49.01M | -49.85M | 54.59M | -2.58M | -87.88M | -1.82M |
| Financing Cash Flow | 164.18M | 75.21M | 622.00K | 30.54M | 180.66K | 904.08K |
Ovid Therapeutics Technical Analysis
Neutral
2.91
Price Trends
2.61
Negative
2.18
Positive
1.82
Positive
Market Momentum
-0.04
Positive
45.79
Neutral
22.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OVID, the sentiment is Neutral. The current price of 2.91 is above the 20-day moving average (MA) of 2.59, above the 50-day MA of 2.61, and above the 200-day MA of 1.82, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 45.79 is Neutral, neither overbought nor oversold. The STOCH value of 22.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OVID.
Ovid Therapeutics Risk Analysis
Ovid Therapeutics disclosed 57 risk factors in its most recent earnings report. Ovid Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ovid Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $220.49M | -3.20 | -41.31% | ― | ― | 73.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $264.81M | -2.19 | -53.61% | ― | -100.00% | 44.78% | |
48 Neutral | $446.07M | ― | -22.51% | ― | 1199.64% | 30.81% | |
48 Neutral | $341.86M | -37.70 | 6068.79% | ― | -12.22% | 30.28% | |
48 Neutral | $93.99M | -2.20 | -196.72% | ― | ― | 74.83% | |
45 Neutral | $285.27M | -0.78 | 309.79% | ― | -35.61% | -68.92% |
* Healthcare Sector Average
OVID
Ovid Therapeutics
2.48
2.17
692.33%
IRD
Opus Genetics
4.64
3.64
364.00%
ZNTL
Zentalis Pharmaceuticals
3.87
2.40
163.27%
IKT
Inhibikase Therapeutics
1.66
-0.30
-15.31%
SRZN
Surrozen
24.38
15.74
182.18%
BMEA
Biomea Fusion
1.37
-1.08
-44.08%
Ovid Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Ovid Therapeutics Expands Board, Appoints New Scientific Director
Positive
Jun 3, 2026
On May 29, 2026, Ovid Therapeutics’ board approved an expansion of its board of directors, effective June 15, 2026, and appointed physician-scientist Anna Greka as a Class III director with a term running until the 2029 annual shareholders&#...
Business Operations and StrategyPrivate Placements and Financing
Ovid Therapeutics Boosts Capital Through Warrant Exercises
Positive
Apr 20, 2026
On April 17, 2026, Ovid Therapeutics Inc. saw the expiration of its Series A Warrants that had been issued in an October 2025 private placement. The warrants covered 38,481,325 common shares, of which investors chose to exercise rights into 33,597...
Business Operations and StrategyPrivate Placements and Financing
Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline
Positive
Mar 18, 2026
On March 17 and 18, 2026, Ovid Therapeutics detailed a $60 million private placement and new clinical data that together underpin an expanded epilepsy pipeline. The company agreed to sell 19.2 million common shares and pre‑funded warrants fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.